| Literature DB >> 498423 |
G Gahrton, M Björkholm, G Brenning, I Christenson, L Engstedt, S Franzén, B Gullbring, G Holm, C Högman, P Hörnsten, S Jameson, A Killander, C Simonsson-Lindemalm, D Lockner, B Lönnqvist, H Mellstedt, J Palmblad, C Paul, C Pauli, C Peterson, P Reizenstein, B Simonsson, K O Skårberg, A M Udén, B Wadman.
Abstract
Forty-four adult patients under 60 years of age with acute nonlymphoblastic leukemia were randomized for induction treatment with one of the following three regimens: R 1 = courses of daunorubicin on day 1 + ARA-C on days 1--5; R 2 = courses of daunorubicin on days 1 and 2 + ARA-C on days 4--8; R 3 = courses of daunorubicin-DNA complex on days 1--2 + ARA-C on days 4--8. Out of 14 patients, 9 went into remission on R 1, 6 out of 14 on R 2, and 8 out of 16 on R 3. The preliminary results suggest that daunorubicin-DNA complex has the same efficacy for inducing remission as daunorubicin alone, if the same time intervals and dosages are used.Entities:
Mesh：
Substances：
Year: 1979 PMID： 498423 DOI： 10.1007/bf00253109
Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333